Approvals/TGA/PAVTIDE ACCUHALER 250/50 fluticasone propionate 250 microgram/salmeterol (as xinafoate) 50 microgram powder for inhalation blister pack

Approved

STANDARD

PAVTIDE ACCUHALER 250/50 fluticasone propionate 250 microgram/salmeterol (as xinafoate) 50 microgram powder for inhalation blister pack

GlaxoSmithKline Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: fe4c2ee8ccbabfc6
Product Name: PAVTIDE ACCUHALER 250/50 fluticasone propionate 250 microgram/salmeterol (as xinafoate) 50 microgram powder for inhalation blister pack
Artg Id: 208201
Artg Name: PAVTIDE ACCUHALER 250/50 fluticasone propionate 250 microgram/salmeterol (as xinafoate) 50 microgram powder for inhalation blister pack
Sponsor: GlaxoSmithKline Australia Pty Ltd
Company Detail Path: /organization/glaxosmithkline-australia-pty-ltd
Artg Date: 2014-05-07
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/42285ee8abb0d1627a9c7b0f6d515ad6.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/42d2a50d04b7da123e45c2f8f98453fb.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

fe4c2ee8ccbabfc6

Type

Standard